Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | DPP3 | Q9NY33 | 3/20 | 0.50 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.49 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 2/20 | 0.49 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20504636 | 1.00 | CAPN1 (0.53) | CAPN1CTSBTACR1DPP3NTSR2 | |
| SCHEMBL20550224 | 0.90 | ECE1 (0.47) | CAPN1CTSBDPP3NTSR2NTSR1 | |
| SCHEMBL21360939 | 0.89 | CAPN1 (0.61) | CAPN1CTSBDPP3NTSR2NTSR1 | |
| SCHEMBL20504595 | 0.86 | ECE1 (0.47) | CAPN1CTSBTACR1ECE1 | |
| SCHEMBL20504594 | 0.86 | ECE1 (0.47) | CAPN1CTSBTACR1ECE1 | |
| SCHEMBL13226652 | 0.85 | CAPN1 (0.54) | CAPN1CTSBTACR1DPP3KISS1R | |
| SCHEMBL30921659 | 0.84 | NTSR2 (0.60) | CAPN1CTSBTACR1DPP3NTSR2 | |
| SCHEMBL12890377 | 0.83 | TACR1 (0.51) | CAPN1CTSBTACR1DPP3GHSR | |
| SCHEMBL23273239 | 0.83 | NTSR2 (0.60) | CAPN1CTSBTACR1DPP3NTSR2 | |
| SCHEMBL30921658 | 0.82 | ITGB2 (0.65) | TACR1DPP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3377515-B1 | GELATINASE INHIBITORS AND USE THEREOF | IPROTEOS S L (ES) | 2019-10-30 | — | — | EP | disclosed |
| EP-3377515-B1 | GELATINASE INHIBITORS AND USE THEREOF | IPROTEOS S L (ES) | 2019-10-30 | — | — | EP | disclosed |
| US-10414797-B2 | Gelatinase inhibitors and use thereof | IPROTEOS S.L (ES) | 2019-09-17 | — | — | US | disclosed |
| US-10414797-B2 | Gelatinase inhibitors and use thereof | IPROTEOS S.L (ES) | 2019-09-17 | — | — | US | disclosed |
| US-20180319839-A1 | GELATINASE INHIBITORS AND USE THEREOF | IPROTEOS S.L (ES) | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414797-B2 | Gelatinase inhibitors and use thereof | MMP8, SERPINE1, MMP9 | CAPN1 460/4885CTSB 439/4885TACR1 3901/4885 |
| US-20180319839-A1 | GELATINASE INHIBITORS AND USE THEREOF | MMP8, SERPINE1, MMP9 | CAPN1 460/4885CTSB 439/4885TACR1 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.